Circulating microRNAs in Patients with Shiga-Toxin-Producing E. coli O104:H4 Induced Hemolytic Uremic Syndrome

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Lorenzen, Johan M ^a,b   Menne, Jan ^b   Schmidt, Bernhard M W ^b   Schmidt, Mascha ^a   Martino, Filippo ^a   Dietrich, Robert ^a,b   Samiri, Senguel ^a,b   Worthmann, Hans ^b   Heeren, Meike ^b   Weissenborn, Karin ^b   Haller, Hermann ^b   Schiffer, Mario ^b   Kielstein, Jan T ^b   Thum, Thomas ^a,c  

^a Institute of Molecular and Translational Therapeutic Strategies (IMTTS)   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 126; MICRORNA 24;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; NEUROLOGIC DISEASE; PLASMAPHERESIS; QUANTITATIVE ANALYSIS; RENAL REPLACEMENT THERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA ISOLATION; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THROMBOCYTE COUNT; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; DISEASE OUTBREAKS; ESCHERICHIA COLI INFECTIONS; EUROPE; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY; MALE; MICRORNAS; MIDDLE AGED; PLATELET COUNT; REAL-TIME POLYMERASE CHAIN REACTION; RENAL REPLACEMENT THERAPY; SHIGA-TOXIGENIC ESCHERICHIA COLI; THROMBOCYTOPENIA;

EID: 84867426274     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047215     Document Type: Article

References (23)

1. Frank C, Werber D, Cramer JP, Askar M, Faber M, et al. (2011) Epidemic profile of shiga-toxin-producing escherichia coli O104:H4 outbreak in germany. N Engl J Med 365(19): 1771-1780.
2. Karpman D, Sartz L, Johnson S, (2010) Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost 36(6): 575-585.
3. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, et al. (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105(35): 13027-13032.
4. Lorenzen JM, Haller H, Thum T, (2011) MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 7(5): 286-294.
5. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, et al. (2007) MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116(3): 258-267.
6. Lorenzen JM, Volkmann I, Fiedler J, Schmidt M, Scheffner I, et al. (2011) Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 11(10): 2221-2227.
7. Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kumpers P, et al. (2011) Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 6(7): 1540-1546.
8. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, et al. (2011) Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 51(5): 872-875.
9. Gupta SK, Bang C, Thum T, (2010) Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet 3(5): 484-488.
10. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105(30): 10513-10518.
11. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, et al. (2011) MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124(6): 720-730.
12. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, et al. (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2(100): ra81.
13. Obrig TG, Moran TP, Brown JE, (1987) The mode of action of shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244(2): 287-294.
14. Moake JL, (2002) Thrombotic microangiopathies. N Engl J Med 347(8): 589-600.
15. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, et al. (2011) Eculizumab in severe shiga-toxin-associated HUS. N Engl J Med 364(26): 2561-2563.
16. Gruppo RA, Rother RP, (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360(5): 544-546.
17. Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, et al. (2003) Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 111(8): 1181-1190.
18. Stahl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, et al. (2008) Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111(11): 5307-5315.
19. Thurman JM, Marians R, Emlen W, Wood S, Smith C, et al. (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4(12): 1920-1924.
20. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV, (1995) Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333(19): 1253-1258.
21. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L, (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25(11): 1256-1264.
22. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, et al. (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signaling in fibroblasts. Nature 456(7224): 980-984.
23. Wiesen JL, Tomasi TB, (2009) Dicer is regulated by cellular stresses and interferons. Mol Immunol 46(6): 1222-1228.